Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Read twice and referred to the Committee on Finance.
Bill introduced
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Lobbying filed by PFIZER INC.
Lobbying filed by NOVARTIS
Lobbying filed by PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Read twice and referred to the Committee on Finance.
| Registrant | Client | Amount | Filed | Period | Issues |
|---|---|---|---|---|---|
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $12.9M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $7.6M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
The lobbying table lists Senate LDA quarterly reports (LD-2) that cite this bill by number and cover a quarter of the 119th Congress. An LD-2 names a bill as “H.R. 1234” with no Congress, so a report on another Congress, which can only concern a different bill with the same number, is left out, even when it was filed after this Congress began. The amount is what the registrant reported for the whole filing, across every issue on it, not spending on this bill. Official actions and the bill summary come from Congress.gov, and votes from the roll-call record. This page no longer pairs the bill with members' stock trades: matching lobbying clients to traded companies by name, and trades to a bill by date, is not something the records establish.
Lobbying filed by AARP
| AARP | AARP | $5.1M | Jul 21, 2025 | 2025Q2 | MMMHCRPHA |
| PFIZER INC. | PFIZER INC. | $4.2M | Apr 21, 2025 | 2025Q1 | BUDHCRMMM |
| NOVARTIS | NOVARTIS | $4.2M | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $4.1M | Apr 21, 2025 | 2025Q1 | MMMHCRPHA |
| PFIZER INC. | PFIZER INC. | $3.5M | Jul 21, 2025 | 2025Q2 | BUDHCRMMM |
| PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION | $3.4M | Jul 21, 2025 | 2025Q2 | MMMHCRPHA |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $3.3M | Apr 21, 2025 | 2025Q1 | PHASCITAX |
| BAYER CORPORATION (CONSOLIDATED REPORT) | BAYER CORPORATION (CONSOLIDATED REPORT) | $3.0M | Apr 21, 2025 | 2025Q1 | AGRMMMTAR |
| SANOFI US SERVICES INC. | SANOFI US SERVICES INC | $2.5M | Apr 21, 2025 | 2025Q1 | MANHCRMMM |
| BAYER CORPORATION (CONSOLIDATED REPORT) | BAYER CORPORATION (CONSOLIDATED REPORT) | $2.5M | Jul 21, 2025 | 2025Q2 | CPTHCRMMM |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | TAKEDA PHARMACEUTICALS AMERICA INC | $1.5M | Jul 21, 2025 | 2025Q2 | BUDMMMHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $1.5M | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| BIOGEN | BIOGEN | $1.4M | Jul 20, 2025 | 2025Q2 | HCRMMMPHA |
| BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | BOEHRINGER INGELHEIM USA CORPORATION | $1.2M | Apr 21, 2025 | 2025Q1 | HCRMMMANI |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | OTSUKA AMERICA PHARMACEUTICAL, INC. | $1.2M | Apr 17, 2025 | 2025Q1 | HCRBUDTAX |
| OTSUKA AMERICA PHARMACEUTICAL, INC. | OTSUKA AMERICA PHARMACEUTICAL, INC. | $1.2M | Jul 18, 2025 | 2025Q2 | TAXVETTAR |
| JOHNSON & JOHNSON SERVICES, INC. | JOHNSON & JOHNSON SERVICES INC | $1.0M | Jul 21, 2025 | 2025Q2 | HCRBUDCPT |
| BIOGEN | BIOGEN | $1.0M | Apr 21, 2025 | 2025Q1 | MMMPHAMAN |
| BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC | BOEHRINGER INGELHEIM USA CORPORATION | $990.0K | Jul 21, 2025 | 2025Q2 | HCRMMMANI |
| EMD SERONO, INC. | EMD SERONO INC | $910.0K | Jul 21, 2025 | 2025Q2 | HCRMMMPHA |
| NEUROCRINE BIOSCIENCES, INC | NEUROCRINE BIOSCIENCES, INC | $910.0K | Apr 21, 2025 | 2025Q1 | MMMHCRBUD |
| EMD SERONO, INC. | EMD SERONO INC | $900.0K | Apr 21, 2025 | 2025Q1 | SCITRDHCR |
| NEUROCRINE BIOSCIENCES, INC | NEUROCRINE BIOSCIENCES, INC | $890.0K | Jul 21, 2025 | 2025Q2 | MMMHCRBUD |
| NOVARTIS | NOVARTIS | $880.0K | Jul 21, 2025 | 2025Q2 | BUDCPTHCR |
| GSK (FKA GLAXOSMITHKLINE INC.) | GSK (FKA GLAXOSMITHKLINE INC.) | $800.0K | Apr 21, 2025 | 2025Q1 | BUDCPTHCR |
| ACADIA PHARMACEUTICALS | ACADIA PHARMACEUTICALS | $500.0K | Jul 21, 2025 | 2025Q2 | TAXHCRMMM |
| TAKEDA PHARMACEUTICALS AMERICA, INC. | TAKEDA PHARMACEUTICALS AMERICA INC | $490.0K | Apr 22, 2025 | 2025Q1 | BUDTAXTRD |
| COVINGTON & BURLING LLP | PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | $420.0K | Apr 21, 2025 | 2025Q1 | CPTHCR |
| COVINGTON & BURLING LLP | PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC | $220.0K | Jul 21, 2025 | 2025Q2 | CPTHCR |
| LUNDBECK LLC | LUNDBECK LLC | $170.0K | Jul 18, 2025 | 2025Q2 | HCRMMMTAX |
| HARMONY BIOSCIENCES | HARMONY BIOSCIENCES | $150.0K | Jul 21, 2025 | 2025Q2 | PHA |
| LUNDBECK LLC | LUNDBECK LLC | $140.0K | Apr 21, 2025 | 2025Q1 | HCRMMMTAX |
| PRIME THERAPEUTICS | PRIME THERAPEUTICS | $100.0K | Jul 16, 2025 | 2025Q2 | HCRMMMTRD |
| PUBLIC CITIZEN | PUBLIC CITIZEN | $98.8K | Jul 21, 2025 | 2025Q2 | BANBUDCIV |
| IONIS PHARMACEUTICALS, INC. | IONIS PHARMACEUTICALS, INC. | $90.0K | Jul 16, 2025 | 2025Q2 | HCRMMMTAX |
| PUBLIC CITIZEN | PUBLIC CITIZEN | $76.6K | Apr 9, 2025 | 2025Q1 | BANBUDCIV |
| DLA PIPER LLP (US) | BIOGEN, INC. | $60.0K | Jul 21, 2025 | 2025Q2 | PHACPTHCR |
| DLA PIPER LLP (US) | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $60.0K | Jul 21, 2025 | 2025Q2 | PHAHCRMMM |
| TODD STRATEGY GROUP | NOVARTIS, INC. | $60.0K | Jul 20, 2025 | 2025Q2 | MMMTARHCR |
| DLA PIPER LLP (US) | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $60.0K | Apr 21, 2025 | 2025Q1 | PHAHCRMMM |
| HEALTHCARE INSTITUTE OF NEW JERSEY | HEALTHCARE INSTITUTE OF NEW JERSEY | $52.7K | Apr 14, 2025 | 2025Q1 | HCR |
| HEALTHCARE INSTITUTE OF NEW JERSEY | HEALTHCARE INSTITUTE OF NEW JERSEY | $52.3K | Jul 7, 2025 | 2025Q2 | HCR |
| WILLIAMS AND JENSEN, PLLC | PHRMA | $50.0K | Jul 21, 2025 | 2025Q2 | HCRBUDDEF |
| CROSSROADS STRATEGIES, LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $50.0K | Jul 19, 2025 | 2025Q2 | HCRMMMBUD |
| THE KPM GROUP DC LLC | SOLENO THERAPEUTICS, INC. | $50.0K | Jul 17, 2025 | 2025Q2 | HCR |
| HORIZON GOVERNMENT AFFAIRS | PHRMA | $50.0K | Jul 8, 2025 | 2025Q2 | HCR |
| WILLIAMS AND JENSEN, PLLC | PHRMA | $50.0K | Apr 21, 2025 | 2025Q1 | MMMHCRBUD |
| PERSONALIZED MEDICINE COALITION | PERSONALIZED MEDICINE COALITION | $46.0K | Jul 21, 2025 | 2025Q2 | HCRBUD |
| DLA PIPER LLP (US) | NOVARTIS | $40.0K | Jul 18, 2025 | 2025Q2 | PHAMEDCPT |
| DESIMONE CONSULTING, LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | $30.0K | Jul 16, 2025 | 2025Q2 | PHA |
| LMH STRATEGIC SOLUTIONS | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA | $30.0K | Jul 15, 2025 | 2025Q2 | MMMPHA |
| DESIMONE CONSULTING, LLC | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | $30.0K | Apr 18, 2025 | 2025Q1 | PHA |
| ELITE STRATEGIC SERVICES | CONSERVATIVES FOR PROPERTY RIGHTS | $25.0K | Apr 7, 2025 | 2025Q1 | CPTHCRLBR |
| FAMILIES USA FOUNDATION, INC. | FAMILIES USA FOUNDATION INC | $18.0K | Jul 17, 2025 | 2025Q2 | HCRMMMPHA |
| ELITE STRATEGIC SERVICES | CONSERVATIVES FOR PROPERTY RIGHTS | $15.0K | Jul 1, 2025 | 2025Q2 | CPTHCRLBR |
| HARNED STRATEGIES LLC | JOB CREATORS NETWORK | $7.5K | Jul 21, 2025 | 2025Q2 | UNMBUDEDU |
| HARNED STRATEGIES LLC | JOB CREATORS NETWORK | $7.5K | Apr 20, 2025 | 2025Q1 | BUDEDUHCR |